Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | FSHR | P23945 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4020789 | 1.00 | NPC1 (0.43) | NPC1RAB9AADRA1BUSP2POLB | |
| SCHEMBL4020787 | 1.00 | NPC1 (0.43) | NPC1RAB9AADRA1BUSP2POLB | |
| SCHEMBL4027966 | 0.90 | ADRA1B (0.48) | ADRA1BUSP2POLBALDH1A1KCNH2 | |
| SCHEMBL4027971 | 0.90 | ADRA1B (0.48) | ADRA1BUSP2POLBALDH1A1KCNH2 | |
| SCHEMBL4022116 | 0.86 | CYP2C9 (0.41) | USP2ALDH1A1KCNH2KMT2AADRA1A | |
| SCHEMBL4019805 | 0.84 | ALDH1A1 (0.41) | NPC1RAB9APOLBALDH1A1TP53 | |
| SCHEMBL4026452 | 0.82 | ALDH1A1 (0.40) | POLBALDH1A1MCHR1KMT2A | |
| SCHEMBL4028159 | 0.81 | ALDH1A1 (0.39) | POLBALDH1A1MCHR1KMT2A | |
| SCHEMBL4021786 | 0.81 | ALDH1A1 (0.42) | NPC1RAB9AALDH1A1TP53GLA | |
| SCHEMBL4019066 | 0.80 | POLB (0.38) | NPC1RAB9AADRA1BUSP2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572814-B2 | 3,5-dibenzoyl-4-phenyl-piperidine anti-cancer compounds | CYTOKINETICS, INCORPORATED (US) | 2009-08-11 | — | — | US | claimed |
| US-20070161674-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2007-07-12 | — | — | US | claimed |
| US-7572814-B2 | 3,5-dibenzoyl-4-phenyl-piperidine anti-cancer compounds | CYTOKINETICS, INCORPORATED (US) | 2009-08-11 | — | — | US | disclosed |
| US-20070161674-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161674-A1 | Certain chemical entities, compositions, and methods | TP53, VHL, RB1 | NPC1 263/4885RAB9A 2228/4885ADRA1B 4417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.